bullish
Eisai Pharmaceutical - Plenty at Stake with Anti-Alzheimer R&D Programs but Lenvima Is Key
251 Views20 Feb 2017 13:18
Eisai had high hopes from breast cancer treatment Halaven (eribulin) and epilepsy treatment Fycompa (perampanel). However, neither of the two has...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 15-minute read)
Discussions
(Paid Plans Only)
x